Lead Partner

Abzena is a bioconjugate- and biologics-focused CDMO that pushes development of novel treatments forward at every stage from discovery through commercial launch. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their investments in human health. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK.



Singzyme’s ligase-based conjugation technology enables the site-specific attachment of a wide variety of payloads to proteins including antibodies and nanobodies. Singzyme’s one-step precision technology allows rapid bioconjugation, including for dual payloads, with controllable Drug-to-Antibody Ratio and low impact on antibody activity / tumour penetration. Singzyme’s technology therefore significantly shortens the ADC development time and helps bring more homogeneous drugs faster to clinics for the benefit of cancer patients

Aj Bio Pharma

Ajinomoto BioPharma Services

Brand Partner

Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India, providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including Corynex® protein expression technology, oligonucleotide synthesis, ADC, HPAPI, biocatalysis, continuous flow manufacturing and more.


Quanta BioDesign

Quanta BioDesign’s dPEG® platform is founded upon discrete MW PEGs, which enable assembly of unique structures with single-molecule precision and without the liabilities associated with hydrophobic carbon-based linkers. Broadly speaking, ADCs combine an antibody’s antigen-targeting properties with a payload’s cell-killing properties. The dPEG® product line facilitates linker architectures that enhance a conjugate’s tumor-targeting properties by altering its physicochemistry, pharmacokinetics, and biodistribution (See
Chemical Linkers in Antibody Drug Conjugates, Royal Society of Chemistry, 2021). Tailoring these properties, through the optimal incorporation of dPEG® components, to shift in vivo delivery from off-target to tumor-targeted pathways has the potential to improve therapeutic margins.


Catalent Biologics

Catalent Biologics provides advanced technologies and solutions for protein and gene therapy development, manufacturing and clinical supply. With technology platforms including GPEx® cell line engineering, SMARTag® bioconjugation and AAV viral vector expression combined with comprehensive analytical services and fill/finish supply, Catalent Biologics is your premier partner for clinical and commercial success.



Exhibition Partner

Veranova is a global leader in the development and manufacturing of specialist and complex active pharmaceutical ingredients for pharma and biotech customers. Veranova’s global team of highly skilled process chemists and analytical scientists possess over a decade of experience developing and scaling up processes for linking small molecule payloads to polymers in support of antibody-drug conjugates and polymer drug conjugates. Learn more at